Retrospective study of 100-day mortality in advanced solid malignancies: Real world experience in a tertiary cancer center from South India
Background: Mortality rate serves as the clinical indicator of the quality of care and appropriateness of clinical decisions. However, Indian data on 100-day mortality in patients with Stage IV disease, post-palliative therapy is lacking. Objectives: The primary objective was to assess 100-day morta...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2025-04-01
|
| Series: | Cancer Research, Statistics, and Treatment |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/crst.crst_239_24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Background:
Mortality rate serves as the clinical indicator of the quality of care and appropriateness of clinical decisions. However, Indian data on 100-day mortality in patients with Stage IV disease, post-palliative therapy is lacking.
Objectives:
The primary objective was to assess 100-day mortality in patients receiving palliative systemic therapy for advanced solid tumors. The secondary objective was to identify associated predictive factors.
Materials and Methods:
This retrospective cohort study included adults (>18 years) with Stage IV solid malignancies, who were planned for palliative systemic therapy at the Medical Oncology department, from a tertiary cancer center in South India over a 6-month period. Data were retrieved from electronic medical records. Mortality within 100-day was confirmed through records and telephonic interviews. Analysis was performed using Statistical package for the Social Sciences (SPSS) Version 25, (IBM Corp.), with P < 0.050 considered significant.
Results:
We included 144 patients in the study. The median age was 53 years (IQR: 43-62), with 19.4% (n = 28) aged >65 years. Males and females were equally represented. Gastrointestinal and biliary cancers were most common (35.4%, n = 51). Metastatic disease was present in 88.2% (n = 127) of cases, of which 11.8% (n = 15) were oligometastatic. The 100-day mortality rate was 16% (n = 23). Subgroup analysis showed that neutrophil-lymphocyte ratio (P, 0.040) and performance status (P, 0.020) significantly influenced mortality.
Conclusion:
In the era of advanced therapeutics, evaluating 100-day mortality provides insight into clinical decision-making for Stage IV patients. Neutrophil-lymphocyte ratio and performance status are key prognostic indicators. |
|---|---|
| ISSN: | 2590-3233 2590-3225 |